Scarica l'app Stockscreener
1.12
1.75%
-0.02
Dopo l'orario di chiusura:
1.21
0.09
+8.04%
Precedente Chiudi:
$1.14
Aprire:
$1.11
Volume 24 ore:
211.54K
Relative Volume:
0.74
Capitalizzazione di mercato:
$54.79M
Reddito:
-
Utile/perdita netta:
$-56.85M
Rapporto P/E:
-0.7184
EPS:
-1.559
Flusso di cassa netto:
-
1 W Prestazione:
-9.68%
1M Prestazione:
-25.33%
6M Prestazione:
-51.09%
1 anno Prestazione:
-85.03%
Intervallo 1D:
$1.07
$1.16
Intervallo di 1 settimana:
$1.07
$1.27
Portata 52W:
$1.07
$7.89
Fractyl Health Inc Stock (GUTS) Company Profile
Nome
Fractyl Health Inc
Settore
Industria
Telefono
781-902-8800
Indirizzo
3 VAN DE GRAAFF DRIVE, BURLINGTON
Confronta GUTS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
1.12 | 54.79M | 0 | -56.85M | 0 | -1.559 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-28 | Iniziato | Evercore ISI | Outperform |
| 2024-02-27 | Iniziato | BofA Securities | Buy |
| 2024-02-27 | Iniziato | Morgan Stanley | Overweight |
Fractyl Health Inc Borsa (GUTS) Ultime notizie
Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025 - Insider Monkey
10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Fractyl Health Reports Positive Early Data Showing Revita® - GlobeNewswire
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation - The Manila Times
Revolutionary Device Cuts Post-GLP-1 Weight Regain by 60% in Breakthrough Study - Stock Titan
Fractyl Health, Inc. (NASDAQ:GUTS) Shares Acquired by Bank of New York Mellon Corp - Defense World
Fractyl Health director Barnes acquires $40,210 in common stock - Investing.com India
Fractyl Health director Ajay Royan purchases $22,979 in common stock By Investing.com - Investing.com Australia
Fractyl Health director Ajay Royan purchases $22,979 in common stock - Investing.com India
FRACTYL HEALTH Executives Increase Their Stakes - TradingView
Fractyl Health director Barnes acquires $40,210 in common stock By Investing.com - Investing.com UK
FRACTYL HEALTH Director Bradley William Acquires 16,129 Shares - TradingView
Fractyl Health sets June 11 for 2025 stockholder meeting - Investing.com
Fractyl Health sets June 11 for 2025 stockholder meeting By Investing.com - Investing.com South Africa
Rhumbline Advisers Boosts Stock Holdings in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks - Yahoo Finance
Fractyl Health Reports 2024 Financial Results and Strategic Progress - MSN
Earnings call transcript: Fractyl Health’s Q4 2024 results miss expectations, stock drops - Investing.com India
FRACTYL HEALTH Earnings Results: $GUTS Reports Quarterly Earnings - Nasdaq
Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates - TradingView
Fractyl Health Highlights Urgent Demand for Weight Maintenance Solutions Post-GLP-1 Therapy in Upcoming REMAIN-1 Study Amid Strategic Focus on Metabolic Health - Nasdaq
Fractyl's Weight Maintenance Study Hits 189 Patients: Can It Solve the GLP-1 Rebound Problem? - StockTitan
Earnings Scheduled For March 3, 2025 - Benzinga
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 - The Manila Times
Fractyl Health to Report Fourth Quarter and Full Year 2024 - GlobeNewswire
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide ... - The Bakersfield Californian
Can This Metabolic Disease Pioneer Deliver Strong Q4 Results? Fractyl Health Reports March 3 - StockTitan
Fractyl Health, Inc. (NASDAQ:GUTS) Sees Significant Drop in Short Interest - MarketBeat
Stratos Wealth Partners LTD. Sells 21,148 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS) - Yahoo Finance
Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments - PharmaVoice
Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) CEO Sells 90,972 Shares of Stock - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Fractyl Health (NASDAQ:GUTS) Price Target Cut to $10.00 by Analysts at Morgan Stanley - MarketBeat
Potential Price Increase for Fractyl Health Inc (GUTS) After Recent Insider Activity - Knox Daily
BlackRock, Inc. Increases Stake in Fractyl Health Inc: A Strategic Move in Biotechnology - GuruFocus.com
Fractyl Health, Inc. (NASDAQ:GUTS) Stock Position Lifted by JPMorgan Chase & Co. - Defense World
Fractyl Health, Inc. (NASDAQ:GUTS) Insider Jay David Caplan Sells 22,346 Shares - MarketBeat
Fractyl Health Inc (GUTS) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Trading Day Triumph: Fractyl Health Inc (GUTS) Ends at 1.70, a -7.61 Surge/Plunge - The Dwinnex
Fractyl Health (NASDAQ:GUTS) Given New $10.00 Price Target at Morgan Stanley - Defense World
FRACTYL HEALTH Executives Sell Shares - TradingView
Fractyl Health announces layoffs as it pivots to gene therapy - Mass Device
Burlington biotech company announces layoffs, pivots research focus - NBC Boston
Fractyl Health Announces Increased Focus on Groundbreaking - GlobeNewswire
Fractyl Health pivots Type 2 diabetes device therapy toward obesity and GLP-1s, lays off 17% of staff - Fierce Biotech
Fractyl Health To Focus On Revita, Rejuva Programs, To Cut Workforce By 17%; Stock Down - Nasdaq
Fractyl Health announces increased focus on Revita, Rejuva programs - TipRanks
Fractyl Health Reprioritizes Focus on REMAIN-1 Study - TipRanks
Fractyl Health Prioritizes Clinical Development of Revita and Advances Rejuva Gene Therapy in Response to Market Demand - Nasdaq
Fractyl Health Inc Azioni (GUTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fractyl Health Inc Azioni (GUTS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barnes Kelly Ann | Director |
Mar 14 '25 |
Buy |
1.30 |
31,000 |
40,210 |
31,000 |
| SCHULMAN AMY W | Director |
Mar 13 '25 |
Buy |
1.17 |
8,550 |
9,964 |
8,550 |
| BRADLEY WILLIAM | Director |
Mar 13 '25 |
Buy |
1.26 |
16,129 |
20,358 |
16,129 |
| Conaway Samuel | Director |
Mar 13 '25 |
Buy |
1.17 |
8,550 |
9,964 |
8,550 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Option Exercise |
1.70 |
90,972 |
154,652 |
582,301 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Option Exercise |
1.70 |
20,948 |
35,612 |
512,277 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Sale |
1.82 |
90,972 |
165,205 |
491,329 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Sale |
1.95 |
20,948 |
40,798 |
491,329 |
| Caplan Jay David | President, Chief Product Off. |
Jan 31 '25 |
Option Exercise |
1.70 |
22,346 |
37,988 |
175,890 |
| Caplan Jay David | President, Chief Product Off. |
Jan 30 '25 |
Option Exercise |
1.70 |
21,472 |
36,502 |
175,016 |
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):